Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ballenger

Showing results (311-320 of 365) with videos related to

Pageof 37
Sort By:
The American Journal of Psychiatry|May 1, 1997
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorderO Brawman-Mintzer, R B Lydiard, J Bradwejn, et al.
Archives of General Psychiatry|May 1, 1988
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatmentJ C Ballenger, G D Burrows, R L DuPont, et al.
Archives of General Psychiatry|May 1, 1988
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safetyR Noyes, R L DuPont, J C Pecknold, et al.
The American Journal of Psychiatry|November 1, 1995
Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity studyO Brawman-Mintzer, R B Lydiard, K A Phillips, et al.
The Journal of Clinical Psychiatry|August 24, 1999
The economic burden of anxiety disorders in the 1990sP E Greenberg, T Sisitsky, R C Kessler, et al.
The Psychiatric Clinics of North America|January 9, 2001
Vagus nerve stimulation. A potential therapy for resistant depression?M S George, H A Sackeim, L B Marangell, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 1, 1995
Long-term follow-up after a drug trial for panic disorderH Katschnig, M Amering, J M Stolk, et al.
Alcoholism, Clinical and Experimental Research|July 9, 1999
Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal periodM S George, C C Tenebäck, R J Malcolm, et al.
The Journal of Clinical Psychiatry|January 20, 2004
Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxietyJames C Ballenger, Jonathan R T Davidson, Yves Lecrubier, et al.
Advances in Biochemical Psychopharmacology|January 11, 1992
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorderJ C Ballenger, S McDonald, R Noyes, et al.
Pageof 37

Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
The American Journal of Psychiatry|May 1, 1997
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorderO Brawman-Mintzer, R B Lydiard, J Bradwejn, et al.
Archives of General Psychiatry|May 1, 1988
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatmentJ C Ballenger, G D Burrows, R L DuPont, et al.
Archives of General Psychiatry|May 1, 1988
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safetyR Noyes, R L DuPont, J C Pecknold, et al.
The American Journal of Psychiatry|November 1, 1995
Body dysmorphic disorder in patients with anxiety disorders and major depression: a comorbidity studyO Brawman-Mintzer, R B Lydiard, K A Phillips, et al.
The Journal of Clinical Psychiatry|August 24, 1999
The economic burden of anxiety disorders in the 1990sP E Greenberg, T Sisitsky, R C Kessler, et al.
The Psychiatric Clinics of North America|January 9, 2001
Vagus nerve stimulation. A potential therapy for resistant depression?M S George, H A Sackeim, L B Marangell, et al.
The British Journal of Psychiatry : the Journal of Mental Science|October 1, 1995
Long-term follow-up after a drug trial for panic disorderH Katschnig, M Amering, J M Stolk, et al.
Alcoholism, Clinical and Experimental Research|July 9, 1999
Multiple previous alcohol detoxifications are associated with decreased medial temporal and paralimbic function in the postwithdrawal periodM S George, C C Tenebäck, R J Malcolm, et al.
The Journal of Clinical Psychiatry|January 20, 2004
Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxietyJames C Ballenger, Jonathan R T Davidson, Yves Lecrubier, et al.
Advances in Biochemical Psychopharmacology|January 11, 1992
The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorderJ C Ballenger, S McDonald, R Noyes, et al.
Pageof 37